Guo Fenfen, Li Hong, Wang Jingjing, Wang Jiangfeng, Zhang Jinling, Kong Fanfang, Zhang Zemin, Zong Jinbao
Departments of Clinical Laboratory, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, People's Republic of China.
Departments of Infectious Disease, Qingdao Women and Children's Hospital, Qingdao, People's Republic of China.
Cancer Manag Res. 2024 Oct 19;16:1491-1507. doi: 10.2147/CMAR.S477698. eCollection 2024.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Tumor immune microenvironment (TIME), angiogenesis, epithelial-mesenchymal transformation (EMT), invasion, metastasis, metabolism, and drug resistance are the main factors affecting the development and treatment of tumors. MiRNAs play crucial roles in almost all major cellular biological processes. Studies have been carried out on miRNAs as biomarkers and therapeutic targets. Their dysregulation contributes to the progression and prognosis of HCC. This review aims to explore the molecular cascades and corresponding phenotypic changes caused by aberrant miRNA expression and their regulatory mechanisms, summarize and analyze novel biomarkers from somatic fluids (plasma/serum/urine), and highlight the latent capacity of miRNAs as therapeutic targets.
肝细胞癌(HCC)是最常见的恶性肿瘤之一。肿瘤免疫微环境(TIME)、血管生成、上皮-间质转化(EMT)、侵袭、转移、代谢和耐药性是影响肿瘤发生发展及治疗的主要因素。微小RNA(miRNA)在几乎所有主要的细胞生物学过程中都发挥着关键作用。针对miRNA作为生物标志物和治疗靶点的研究已经展开。它们的失调促进了HCC的进展和预后。本综述旨在探讨由异常miRNA表达引起的分子级联反应和相应的表型变化及其调控机制,总结和分析来自体液(血浆/血清/尿液)的新型生物标志物,并强调miRNA作为治疗靶点的潜在能力。